Murata HCR Redefines Automotive Timing Devices With the Total Frequency Tolerance of ±40PPM Under -40°C to +125°C Operation
14.11.2024 03:00:00 CET | Business Wire | Press release
Murata Manufacturing Co., Ltd. (TOKYO:6981) (ISIN:JP3914400001) unveils a cutting-edge electronic timing device featuring exceptional accuracy ±40ppm and reliability even in wide-temperature -40°C to +125°C conditions. By addressing the limitations of current timing components in automotive electronic systems, it enhances the design and deployment of next-generation In-Vehicle Networks (IVN), wireless communication, and Advanced Driver Assistance Systems (ADAS) functions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241113670074/en/
Murata Manufacturing Co., Ltd.: The new Timing Devices, XRCGE_M_F series (Photo: Business Wire)
As the automotive industry continues to pursue greater integration and electronic downsizing to address the expanding number of critical electronic systems, the performance requirements for components are growing. In order to achieve tighter packaging without compromising accuracy, it is now necessary for critical components like timing devices to have higher temperature limits. There is also a growing demand to incorporate features like Bluetooth® Low Energy (BLE) and ethernet in vehicles, which demands more accurate timing than what is typically offered by automotive crystal units.
Murata’s high accuracy and high temp automotive crystal (HCR), or XRCGE_M_F series, redefines timing component performance and reliability. It sets a new global standard as the first of its kind to achieve a total frequency tolerance of ±40 ppm throughout an operating temperature range of -40°C to +125°C. This combination allows automotive engineers to achieve the stable and highly accurate timing without the need for system calibration or temperature compensation measures, reducing development efforts and costs.
Murata has a long-standing history of being at the forefront of automotive timing solutions, starting with the introduction of its ceramic resonators in 1997 and followed by its crystal units in 2015 – HCR is the next step. Through the optimization of artificial crystal growth, assembly, and inspection, Murata’s groundbreaking resin-sealed package technology, along with the optimization of crystal design, allows HCR to achieve high-temperature operation and high accuracy. This combination is perfectly suited to support the latest vehicle communication and safety functions such as CAN and ethernet IVNs, ADAS components like cameras, LIDAR, and RADAR, as well as wireless communication technologies such as RF, NFC, BLE, ZigbeeTM, and UWB.
“HCR is a true step forward that perfectly aligns with the latest automotive demands,” said Munenori Hikita, Director of Functional Devices Division at Murata. “With our ‘world’s first’ solution, engineers will be able to deploy downsized designs and high performance communication circuits without compromise.”
The HCR lineup is underpinned by Murata’s stable and reliable multi-source supply chain, ensuring automotive users have no concerns over supply, while its high temperature operating window and strong resistance to solder cracks guarantee long-term reliability. The components have already entered mass production and samples are available upon request. To learn more or to request samples, please contact your local Murata’s representative or visit here.
Please contact us for details: contact form
View source version on businesswire.com: https://www.businesswire.com/news/home/20241113670074/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom